Clinical management of metastatic colorectal cancer in the era of precision medicine
F Ciardiello, D Ciardiello, G Martini… - CA: a cancer journal …, 2022 - Wiley Online Library
Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …
[HTML][HTML] Comprehensive review of targeted therapy for colorectal cancer
YH Xie, YX Chen, JY Fang - Signal transduction and targeted therapy, 2020 - nature.com
Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …
[HTML][HTML] EGFR in cancer: Signaling mechanisms, drugs, and acquired resistance
ML Uribe, I Marrocco, Y Yarden - Cancers, 2021 - mdpi.com
Simple Summary Growth factors are hormone-like molecules able to promote division and
migration of normal cells, but cancer captured the underlying mechanisms to unleash tumor …
migration of normal cells, but cancer captured the underlying mechanisms to unleash tumor …
[HTML][HTML] Patient-derived xenograft models in cancer therapy: technologies and applications
Patient-derived xenograft (PDX) models, in which tumor tissues from patients are implanted
into immunocompromised or humanized mice, have shown superiority in recapitulating the …
into immunocompromised or humanized mice, have shown superiority in recapitulating the …
[HTML][HTML] Patient-derived xenograft (PDX) models, applications and challenges in cancer research
S Abdolahi, Z Ghazvinian, S Muhammadnejad… - Journal of Translational …, 2022 - Springer
The establishing of the first cancer models created a new perspective on the identification
and evaluation of new anti-cancer therapies in preclinical studies. Patient-derived xenograft …
and evaluation of new anti-cancer therapies in preclinical studies. Patient-derived xenograft …
HER2-targeted therapies—a role beyond breast cancer
DY Oh, YJ Bang - Nature reviews Clinical oncology, 2020 - nature.com
HER2 is an established therapeutic target in a large subset of women with breast cancer; a
variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab …
variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab …
Colorectal cancer
E Dekker, PJ Tanis, JLA Vleugels, PM Kasi… - The Lancet, 2019 - thelancet.com
Several decades ago, colorectal cancer was infrequently diagnosed. Nowadays, it is the
world's fourth most deadly cancer with almost 900 000 deaths annually. Besides an ageing …
world's fourth most deadly cancer with almost 900 000 deaths annually. Besides an ageing …
Precision oncology in metastatic colorectal cancer—from biology to medicine
Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …
therapies for patients with multiple cancer types, including melanoma, breast and lung …
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
V Amodio, R Yaeger, P Arcella, C Cancelliere… - Cancer discovery, 2020 - AACR
Most patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC) experience
clinical benefit from selective KRASG12C inhibition, whereas patients with colorectal cancer …
clinical benefit from selective KRASG12C inhibition, whereas patients with colorectal cancer …
[HTML][HTML] Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial
Y Nakamura, W Okamoto, T Kato, T Esaki, K Kato… - Nature medicine, 2021 - nature.com
The applicability of circulating tumor DNA (ctDNA) genotyping to inform enrollment of
patients with cancer in clinical trials has not been established. We conducted a phase 2 trial …
patients with cancer in clinical trials has not been established. We conducted a phase 2 trial …